Literature DB >> 18807245

Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.

Massimo Ibba1, Masato Kitayama, John McDonald, Girolamo Calo, Remo Guerrini, Judit Farkas, Geza Toth, David G Lambert.   

Abstract

Nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand for the N/OFQ peptide receptor (NOP). Binding studies have relied on [leucyl-(3)H]N/OFQ, but as this is an agonist G-protein coupling will affect affinity. In this paper, we describe a new [(3)H]labeled NOP antagonist, [Nphe(1),4'-(3)H-Phe(4),Arg(14),Lys(15)]N/OFQ-NH(2) ([(3)H]UFP-101). We have characterized [(3)H]UFP-101 at recombinant human NOP expressed in Chinese hamster ovary cells (CHO(hNOP)) and native rat NOP in cerebrocortex. Radioligand saturation and competition studies were performed on membranes, and [(3)H]UFP-101 (antagonist) was compared with [(3)H]N/OFQ (agonist). The effects of GTPgammaS (10 microM) and Na(+) were investigated alone and in combination in competition experiments with both radioligands. In CHO(hNOP), B (max), and pK (D), values were 561 and 580 fmol mg protein(-1) and 9.97 and 10.19 for [(3)H]UFP-101 and [leucyl-(3)H]N/OFQ, respectively. In rat cerebrocortex B (max) and pK (D), values were 65 and 88 fmol mg protein(-1) and 10.12 and 10.34 for [(3)H]UFP-101 and [leucyl-(3)H]N/OFQ. The binding of both radioligands was displaced by a range of peptide and non-peptide NOP ligands at both isoforms with good correlation (r (2) 0.92 in Rat and 0.97 in CHO(hNOP)). Naloxone was inactive. The binding of both radioligands was Na(+)-dependent with [(3)H]UFP-101 being more sensitive (IC(50) approximately20 mM). Unlike the agonist [leucyl-(3)H]N/OFQ, the antagonist [(3)H]UFP-101 was unaffected by GTPgammaS. [(3)H]UFP-101 binds to human and rat NOP with high affinity and good agreement with standard [leucyl-(3)H]N/OFQ in competition experiments. In addition, the binding of [(3)H]UFP-101 is unaffected by GTPgammaS. This radioligand will be useful to further characterize NOP in a range of binding paradigms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18807245     DOI: 10.1007/s00210-008-0350-3

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  41 in total

1.  Highly potent nociceptin analog containing the Arg-Lys triple repeat.

Authors:  K Okada; T Sujaku; Y Chuman; R Nakashima; T Nose; T Costa; Y Yamada; M Yokoyama; A Nagahisa; Y Shimohigashi
Journal:  Biochem Biophys Res Commun       Date:  2000-11-19       Impact factor: 3.575

Review 2.  Cellular actions of nociceptin: transduction mechanisms.

Authors:  B E Hawes; M P Graziano; D G Lambert
Journal:  Peptides       Date:  2000-07       Impact factor: 3.750

Review 3.  Orphanin FQ/nociceptin receptor binding studies.

Authors:  C T Dooley; R A Houghten
Journal:  Peptides       Date:  2000-07       Impact factor: 3.750

4.  [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.

Authors:  Girolamo Calo; Anna Rizzi; Daniela Rizzi; Raffaella Bigoni; Remo Guerrini; Giuliano Marzola; Matteo Marti; John McDonald; Michele Morari; David G Lambert; Severo Salvadori; Domenico Regoli
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

5.  UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.

Authors:  J McDonald; G Calo; R Guerrini; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-15       Impact factor: 3.000

6.  N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.

Authors:  Remo Guerrini; Girolamo Caló; David G Lambert; Giacomo Carrá; Marika Arduin; Tim A Barnes; John McDonald; Daniela Rizzi; Claudio Trapella; Erika Marzola; David J Rowbotham; Domenico Regoli; Severo Salvadori
Journal:  J Med Chem       Date:  2005-03-10       Impact factor: 7.446

7.  Comparison of the binding of [(3)H]nociceptin/orphaninFQ(1-13)NH(2), [(3)H]nociceptin/orphaninFQ(1-17)OH and [(125)I]Tyr(14)nociceptin/orphaninFQ(1-17)OH to recombinant human and native rat cerebrocortical nociceptin/orphanin FQ receptors.

Authors:  E Hashiba; D G Lambert; J Farkas; G Toth; G Smith
Journal:  Neurosci Lett       Date:  2002-08-02       Impact factor: 3.046

8.  Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?

Authors:  Hanns Ulrich Zeilhofer; Girolamo Calò
Journal:  J Pharmacol Exp Ther       Date:  2003-04-29       Impact factor: 4.030

9.  Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships.

Authors:  K Varani; G Calo; A Rizzi; S Merighi; G Toth; R Guerrini; S Salvadori; P A Borea; D Regoli
Journal:  Br J Pharmacol       Date:  1998-12       Impact factor: 8.739

10.  Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes.

Authors:  U Gether; S Lin; B K Kobilka
Journal:  J Biol Chem       Date:  1995-11-24       Impact factor: 5.157

View more
  9 in total

1.  How reliable are G-protein-coupled receptor antibodies?

Authors:  Martin C Michel; Thomas Wieland; Gozoh Tsujimoto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-27       Impact factor: 3.000

2.  Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.

Authors:  M F Bird; R S Vardanyan; V J Hruby; G Calò; R Guerrini; S Salvadori; C Trapella; J McDonald; D J Rowbotham; D G Lambert
Journal:  Br J Anaesth       Date:  2015-02-13       Impact factor: 9.166

3.  Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13).

Authors:  Maria Camilla Cerlesi; Huiping Ding; Mark F Bird; Norikazu Kiguchi; Federica Ferrari; Davide Malfacini; Anna Rizzi; Chiara Ruzza; David G Lambert; Mei-Chuan Ko; Girolamo Calo; Remo Guerrini
Journal:  Eur J Pharmacol       Date:  2016-11-19       Impact factor: 4.432

4.  In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.

Authors:  A Rizzi; D Malfacini; M C Cerlesi; C Ruzza; E Marzola; M F Bird; D J Rowbotham; S Salvadori; R Guerrini; D G Lambert; G Calo
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 5.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

Review 6.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

7.  Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats.

Authors:  Giovanni Vitale; Valentina Ruggieri; Monica Filaferro; Claudio Frigeri; Silvia Alboni; Fabio Tascedda; Nicoletta Brunello; Remo Guerrini; Carlo Cifani; Maurizio Massi
Journal:  Psychopharmacology (Berl)       Date:  2009-08-27       Impact factor: 4.530

8.  Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).

Authors:  Mark F Bird; Maria Camilla Cerlesi; Mark Brown; Davide Malfacini; Vanessa Vezzi; Paola Molinari; Laura Micheli; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Remo Guerrini; Girolamo Calò; David G Lambert
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

9.  The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.

Authors:  Zoë L S Brookes; Emily N Stedman; Nicola J Brown; Christopher P Hebbes; Remo Guerrini; Girolamo Calo; Charles S Reilly; David G Lambert
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.